Serial No.: 09/405,735 -2 - Art Unit: 1637

Conf. No.: 9816

In the Claims

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikeouts and/or double bracketing.

Please amend pending claims 35 and 36 as noted below.

1-13. (Canceled)

14. (Previously Presented) A pharmaceutical preparation comprising a CFTR expression regulator, wherein the CFTR expression regulator is a polysaccharide that is an LPS core moiety comprising

wherein X is selected from the group consisting of glucose, glucose-rhamnose and H; wherein Y is selected from the group consisting of rhamnose and H; and wherein Z is selected from the group consisting of glucose and H; and a pharmaceutically acceptable carrier.

15. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises

16. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises

$$\begin{array}{ccccc} Y & Z & PO_4 \\ & | & | & | \\ X & - Glc & - & GalN - Hep & - Hep & - \end{array}$$

Serial No.: 09/405,735

Conf. No.: 9816

Art Unit: 1637

17. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises

- 3 -

18. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises

$$\alpha$$
-Rha α -Glc \downarrow^{1}_{6} \downarrow^{1}_{7} α - Glc - (1 \rightarrow 6) - β - Glc ρ - (1 \rightarrow 3) - α - D - Gal ρ N - Hep - KDO - KDO alanine

19. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises

$$\alpha$$
-Rha α -Glc ↓ ↓ ↓ α - Glc - (1→6) - β - Glc ρ - (1→3) - α - D - Gal ρ N - Hep - (1-4/5) - β KDO - (2→4/5) - KDO ↓ alanine

20. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises

$$\alpha$$
-L-Rha B-D-Glcp | α - D - Glcp - $(1 \rightarrow 3)$ - α - D - Glcp - $(1 \rightarrow 4)$ - α - D - GalpN - $(1 \rightarrow 3)$ - alanine

CONH₂ PO₄ | CONH₂ | PO₄ |
$$\alpha$$
 - KDO α

Serial No.: 09/405,735 - 4 - Art Unit: 1637

Conf. No.: 9816

21. (Original) The pharmaceutical preparation of claim 14 wherein the polysaccharide comprises a CFTR binding fragment of a lipopolysaccharide of *Pseudomonas aeruginosa*.

- 22. (Previously Presented) The pharmaceutical preparation of claim 14 wherein the pharmaceutical preparation is sterile.
- 23. (Previously Presented) The pharmaceutical preparation of claim 14 wherein the pharmaceutical preparation is formulated in a unit dosage in an amount effective for treating *Pseudomonal* infection.
- 24. (Previously Presented) The pharmaceutical preparation of claim 14 wherein the pharmaceutical preparation is formulated as an aerosol for inhalation.
- 25. (Previously Presented) The pharmaceutical preparation of claim 14 wherein the pharmaceutical preparation is formulated as an injectable preparation.
 - 26. (Previously Presented) A composition of matter comprising a covalent conjugate of a non-toxic lipid and a polysaccharide comprising

wherein X is selected from the group consisting of glucose, glucose-rhamnose and H; Y is selected from the group consisting of rhamnose and H; and Z is selected from the group consisting of glucose and H.

27. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises

Art Unit: 1637

Serial No.: 09/405,735

Conf. No.: 9816

28. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises

29. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises

$$\begin{array}{c|cccc} & Y & Z & PO_4 \\ & & & & | & & | \\ X & - & Glc & - & GalN & - & Hep & - & Hep & - & KDO & - \\ & & & & & | & & | \\ & & & & & alanine & PO_4 \end{array}$$

30. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises

31. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises

32. (Previously Presented) The composition of matter of claim 26 wherein the polysaccharide comprises

$$\alpha$$
-L-Rha B-D-Glcp | α - D - Glc ρ - (1 \rightarrow 3) - α - D - Glc ρ - (1 \rightarrow 4) - α - D - Gal ρ N - (1 \rightarrow 3) - alanine

Serial No.: 09/405,735 - 6 - Art Unit: 1637

Conf. No.: 9816

CONH₂ PO₄ | L -
$$\alpha$$
 - D - Hep - (1 \rightarrow 3) - L - α - D - Hep - (1 \rightarrow 5) - α - KDO ρ | α - KDO ρ

- 33. (Original) The composition of matter of claim 26 wherein the polysaccharide comprises a CFTR binding fragment of a lipopolysaccharide of *Pseudomonas aeruginosa*.
- 34. (Previously Presented) The composition of matter of claim 26 wherein the lipid has the following structural formula: CH₃(CH₂)_nCOOH wherein n=1-50.
- 35. (Currently amended) The composition of matter of claim 34 wherein the lipid wherein the lipid is in the wall of a liposome containing a bioactive agent, wherein the bioactive agent is selected from the group consisting of a diagnostic molecule, a molecule affecting metabolism of a cell, an anti-microbial molecule and a therapeutic molecule.
- 36. (Currently amended) A composition of matter comprising
 a covalent conjugate of a bioactive agent wherein the bioactive agent is
 selected from the group consisting of a diagnostic molecule, a molecule affecting metabolism of
 a cell, an anti-microbial molecule and a therapeutic molecule, and a polysaccharide comprising

wherein X is selected from the group consisting of glucose, glucose-rhamnose and H; Y is selected from the group consisting of rhamnose and H; and Z is selected from the group consisting of glucose and H.

37. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises

Conf. No.: 9816

- 7 -

Art Unit: 1637

ı

38. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises

alanine

39. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises

40. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises

41. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises

42. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises

Serial No.: 09/405,735

- 8 -

Art Unit: 1637

Conf. No.: 9816

$$\alpha$$
 - D - Glcp - (1 \rightarrow 3) - α - D - Glcp - (1 \rightarrow 4) - α - D - GalpN - (1 \rightarrow 3) - alanine

43. (Original) The composition of matter of claim 36 wherein the polysaccharide comprises a CFTR binding fragment of a lipopolysaccharide of *Pseudomonas aeruginosa*.

44-68. (Canceled)